[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100472762":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":47,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":20,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-ACN376","EXPERIMENTAL","Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-ACN376 PET\u002FCT scan.",[13],"Drug: 18F-FDG",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","18F-FDG","All study participants will undergo one 18F-FDG PET\u002FCT scan.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Hua Zhu","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","010-88196495","zhuhuabch@pku.edu.cn",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Beijing cancer hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"type":24,"investigatorFullName":23,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Associate Professor","100472762","cldn182-targeting-nanobody-probe-for-pet-imaging-in-solid-tumors-100472762",false,"NCT05436093","CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors","Inclusion Criteria:\n\n* 1\\. Aged \\>18 years old; ECOG 0 or 1;\n* 2\\. Patients with solid tumors;\n* 3\\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);\n* 4\\. life expectancy \\>=12 weeks.\n\nExclusion Criteria:\n\n* 1\\. Significant hepatic or renal dysfunction;\n* 2\\. Is pregnant or ready to pregnant;\n* 3\\. Cannot keep their states for half an hour;\n* 4\\. Refusal to join the clinical study;\n* 5\\. Suffering from claustrophobia or other mental diseases;\n* 6\\. Any other situation that researchers think it is not suitable to participate in the experiment.","ALL","18 Years","75 Years",{"count":59,"type":60},15,"ESTIMATED","INTERVENTIONAL",[63],"NA","The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET\u002FCT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.",[66],"Solid Tumor","2026-03-02",{"date":69,"type":70},"2026-03-04","ACTUAL",{"date":72,"type":70},"2022-06-23",{"date":74,"type":60},"2027-12",{"name":5,"class":6},1]